Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors

The incidence of severe immune-related adverse events (irAEs) in cancer subjects receiving immune checkpoint inhibitors (ICIs) following COVID-19 vaccination and the relationship between the incidence of severe irAE and the interval between COVID-19 vaccination and ICI dose have not been established...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilbert, Danielle, Hu, Junxiao, Medina, Theresa, Kessler, Elizabeth R., Lam, Elaine T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Coronavirus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294768/
https://www.ncbi.nlm.nih.gov/pubmed/37157982
http://dx.doi.org/10.1080/21645515.2023.2207438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294768/
https://www.ncbi.nlm.nih.gov/pubmed/37157982
http://dx.doi.org/10.1080/21645515.2023.2207438

Ejemplares similares